Indication
Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Medicine details
- Medicine name:
- elafibranor (Iqirvo)
- SMC ID:
- SMC2714
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC